Yisuda^®Suraxavir Marboxil Tablets were approved for marketing in March 2025. Developed independently by KVVIT, a subsidiary of Qingfeng Pharmaceutical Group, this Class 1 innovative antiviral drug is also China’s first domestically developed RNA polymerase inhibitor (targeting the PA site). It is indicated for the treatment of previously healthy adolescents aged 12 and older and adults with uncomplicated influenza A and B.

Yisuda^®Suraxavir Marboxil Tablets target the core engine of viral replication by inhibiting the CAP-dependent nucleoclease of the influenza virus, precisely blocking viral replication and requiring only a single dose throughout the entire course of the illness.

According to Phase III clinical trial data, compared with placebo, Isuda^® Masulavir tablets resulted in a faster decline in viral load from baseline on Day 1 after dosing. Compared with the placebo group, the median time to resolution of influenza symptoms was reduced by 21 hours, and the median time to resolution of fever was reduced by 8.6 hours. viral clearance time was reduced by 25 hours, and fever resolution time by 19.7 hours. This achieves the therapeutic effect of “a single dose for the entire course of treatment, clearing the virus and resolving fever within one day,” with a drug resistance mutation rate of less than 1%, which is significantly lower than that of similar international drugs.

The results of the Phase III clinical trial were published on January 7, 2025, in *Nature Medicine* (Impact Factor: 58.7), a leading global medical research journal.

Wang Dayan, a researcher at the National Institute for Viral Disease Control and Prevention under the Chinese Center for Disease Control and Prevention, stated at a press conference held by the National Health Commission on December 5 that influenza activity is currently at a high level in 17 provinces nationwide, while the remaining provinces are at a moderate level. The positive rate for influenza virus testing among patients with influenza-like symptoms visiting outpatient and emergency departments has reached 51%. The influenza A (H3N2) subtype remains the dominant strain, accounting for over 95% of cases, with a small number of influenza A (H1N1) and influenza B viruses circulating concurrently. The successful inclusion of Isudata^® (Mashulavir) tablets in the national medical insurance coverage is like a “timely rain,” which will significantly improve the accessibility and affordability of medication for domestic influenza patients, effectively providing them with a more economical, effective, and safe treatment option.

Langkang^® Perampanel Oral Suspension

 

Perampanel Oral Suspension is indicated for the treatment of partial seizures (with or without secondary generalization) in adults and children aged 4 years and older. It is the first oral suspension formulation developed by KVVIT, a subsidiary of Qingfeng Pharmaceutical Group. When at rest, the medication has a semi-solid, jelly-like consistency; however, gently shaking it for 5 seconds transforms it into a free-flowing liquid. Its highly dispersed, uniform formulation allows for precise dose adjustment, making it particularly suitable for children, elderly patients, and those with difficulty swallowing. Additionally, while most currently available antiepileptic drugs require twice-daily dosing, the pirfenamide formulation is taken only once daily, at bedtime, thereby improving medication adherence.

In recent years, kvvit has responded to the national call by fully embracing the national medical insurance negotiation and centralized drug procurement policies. Several of its drugs have been included in the National Medical Insurance Directory, and nearly 20 products have been selected through national centralized procurement. The company has played a significant role in replacing imported drugs and reducing the financial burden on patients, thereby effectively addressing unmet clinical needs in China. Moving forward, Kvvit will adhere to a research and development-driven growth strategy, focusing on unmet clinical needs. We will dedicate ourselves to R&D and commit to manufacturing with craftsmanship, striving to provide more high-quality, affordable medicines to patients worldwide.